{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T22:13:02Z","timestamp":1781734382525,"version":"3.54.5"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.japh.2026.103043","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T16:53:19Z","timestamp":1770828799000},"page":"103043","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Economic evaluation of talazoparib and enzalutamide compared to enzalutamide monotherapy in HRRm metastatic castration-resistant prostate cancer"],"prefix":"10.1016","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-0107-6798","authenticated-orcid":false,"given":"Caiden","family":"Lukan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7906-9398","authenticated-orcid":false,"given":"Kangho","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.japh.2026.103043_bib1","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/jama.2025.0228","article-title":"Prostate cancer: a review","volume":"333","author":"Raychaudhuri","year":"2025","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.japh.2026.103043_bib3","doi-asserted-by":"crossref","first-page":"566","DOI":"10.7326\/0003-4819-132-7-200004040-00009","article-title":"Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis","volume":"132","author":"Seidenfeld","year":"2000","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.japh.2026.103043_bib4","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.japh.2026.103043_bib5","doi-asserted-by":"crossref","DOI":"10.1177\/17588359251356109","article-title":"HRR deficiency-guided use of talazoparib plus enzalutamide in patients with metastatic castration-resistant prostate cancer: a cost-effectiveness analysis","volume":"17","author":"Rui","year":"2025","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"10.1016\/j.japh.2026.103043_bib6","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/bju.16462","article-title":"Impact of homologous recombination repair\/BReast CAncer (BRCA) gene alterations on survival in a real-world setting of metastatic prostate cancer","volume":"135","author":"Wenzel","year":"2025","journal-title":"BJU Int"},{"key":"10.1016\/j.japh.2026.103043_bib7","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.euros.2022.04.016","article-title":"Enzalutamide versus abiraterone plus prednisolone before chemotherapy for castration-resistant prostate cancer: a multicenter randomized controlled trial","volume":"41","author":"Izumi","year":"2022","journal-title":"Eur Urol Open Sci"},{"issue":"5","key":"10.1016\/j.japh.2026.103043_bib8","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"issue":"10502","key":"10.1016\/j.japh.2026.103043_bib9","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0140-6736(25)00683-X","article-title":"Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial","volume":"406","author":"Fizazi","year":"2025","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.japh.2026.103043_bib10","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S1470-2045(25)00030-0","article-title":"First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial","volume":"26","author":"Matsubara","year":"2025","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.japh.2026.103043_bib11","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3390\/cancers17010040","article-title":"Cost-Effectiveness of PARP inhibitors for patients with BRCA1\/2-Positive metastatic castration-resistant prostate cancer-the Canadian perspective","volume":"17","author":"Yanev","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"15","key":"10.1016\/j.japh.2026.103043_bib12","doi-asserted-by":"crossref","first-page":"830","DOI":"10.21037\/atm-22-3637","article-title":"Cost-effectiveness of olaparib, a PARP inhibitor, for patients with metastatic castration-resistant prostate cancer in China and United States","volume":"10","author":"Xu","year":"2022","journal-title":"Ann Transl Med"},{"issue":"1","key":"10.1016\/j.japh.2026.103043_bib13","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jval.2021.10.008","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II good practices task force","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"key":"10.1016\/j.japh.2026.103043_bib14","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/1471-2288-11-139","article-title":"Improved curve fits to summary survival data: application to economic evaluation of health technologies","volume":"11","author":"Hoyle","year":"2011","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.japh.2026.103043_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104286","article-title":"Second-line treatment options in metastatic castration-resistant prostate cancer after progression on first-line androgen-receptor targeting therapies: a systematic review and Bayesian network analysis","volume":"196","author":"Xiong","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.japh.2026.103043_bib16","unstructured":"Therneau T. A Package for survival analysis in R. R package version 3.8-3 Available at: https:\/\/CRAN.R-project.org\/package=survival, 2024. [Accessed 1 May 2025]."},{"issue":"8","key":"10.1016\/j.japh.2026.103043_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v070.i08","article-title":"Flexsurv: a platform for parametric survival modeling in R","volume":"70","author":"Jackson","year":"2016","journal-title":"J Stat Softw"},{"issue":"3","key":"10.1016\/j.japh.2026.103043_bib19","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1177\/0272989X07300604","article-title":"A review and meta-analysis of prostate cancer utilities","volume":"27","author":"Bremner","year":"2007","journal-title":"Med Decis Making"},{"issue":"1","key":"10.1016\/j.japh.2026.103043_bib25","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/13696998.2024.2303890","article-title":"Real-world economic burden of metastatic castration-resistant prostate cancer before and after first-line therapy initiation","volume":"27","author":"Kaye","year":"2024","journal-title":"J Med Econ"},{"issue":"1","key":"10.1016\/j.japh.2026.103043_bib26","first-page":"92","article-title":"Hospice or hospital: the costs of dying of cancer in the oncology care model","volume":"1","author":"Hoverman","year":"2020","journal-title":"Palliat Med Rep"},{"issue":"8","key":"10.1016\/j.japh.2026.103043_bib28","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2024.2530","article-title":"Drug prices after patent expirations in high-income countries and implications for cost-effectiveness analyses","volume":"5","author":"Serra-Burriel","year":"2024","journal-title":"JAMA Health Forum"},{"issue":"6","key":"10.1016\/j.japh.2026.103043_bib29","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.jval.2012.06.012","article-title":"Modeling good research practices--overview: a report of the ISPOR-SMDM modeling good research practices task force--1","volume":"15","author":"Caro","year":"2012","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.japh.2026.103043_bib30","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.jval.2023.01.004","article-title":"The zero-price conundrum: exploration of scenarios where a clinically effective new drug might not be cost-effective at zero price","volume":"26","author":"Mladsi","year":"2023","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.japh.2026.103043_bib31","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40273-014-0206-2","article-title":"Pertuzumab in combination with trastuzumab and docetaxel for the treatment of HER2-positive metastatic or locally recurrent unresectable breast cancer","volume":"33","author":"Fleeman","year":"2015","journal-title":"Pharmacoeconomics"},{"issue":"10398","key":"10.1016\/j.japh.2026.103043_bib32","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.japh.2026.103043_bib33","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12885-020-07754-9","article-title":"Cost-effectiveness analysis of cabazitaxel for metastatic castration resistant prostate cancer after docetaxel and androgen-signaling-targeted inhibitor resistance","volume":"21","author":"Zhang","year":"2021","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.japh.2026.103043_bib34","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1093\/jnci\/djad135","article-title":"Cost-effectiveness analysis of 7 treatments in metastatic hormone-sensitive prostate cancer: a public-payer perspective","volume":"115","author":"Yoo","year":"2023","journal-title":"J Natl Cancer Inst"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319126000282?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319126000282?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T19:37:13Z","timestamp":1780947433000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319126000282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1544319126000282"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2026.103043","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Economic evaluation of talazoparib and enzalutamide compared to enzalutamide monotherapy in HRRm metastatic castration-resistant prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2026.103043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of the American Pharmacists Association.","name":"copyright","label":"Copyright"}],"article-number":"103043"}}